This excerpt taken from the UNH 8-K filed Dec 19, 2006.
FDA SELECTS INGENIX FOR DRUG SAFETY MONITORING AND SUPPORT
BASKING RIDGE, NJ (Sept. 28, 2005) Ingenix, a wholly owned subsidiary of UnitedHealth Group (NYSE: UNH), has been selected by the United States Food and Drug Administration (FDA) to help improve the effectiveness and speed of safety evaluations for pharmaceutical agents. The Ingenix program is built around a team of leading epidemiologists, complex analytic tools, and the largest and most complete longitudinal patient database available today. It will work with the FDA to monitor the safety of new drugs as well as conduct ad hoc safety studies on established pharmaceutical agents.
We are pleased to provide our extensive data resources and analytic capabilities to help the FDA respond to the urgent need for improved drug safety, said Terri Madison, PhD, MPH, president of i3 Drug Safety which will lead the Ingenix program. These proactive efforts should enhance the FDAs ability to identify and assess issues and potential risks related to pharmaceutical agents in a more timely fashion than ever before.